TOP RANKED GLOBAL ADVISOR ROSEN Encourages ASP Isotopes Inc. Investors to Get Advice Ahead of Important Deadline in Securities Class Action Lawsuit
TOP RANKED GLOBAL ADVISOR ROSEN Encourages ASP Isotopes Inc. Investors to Get Advice Ahead of Important Deadline in Securities Class Action Lawsuit



New York, New York–(Newsfile Corp. – December 25, 2024)- BECAUSE: Rosen Law Firm, a global investor rights law firm, reminds buyers of securities of ASP Isotopes Inc. (NASDAQ: ASPI) between October 30, 2024 and November 26, 2024, both dates inclusive ( the “Class Period”), the important February 3, 2025 Lead Plaintiff Deadline.

SO WHAT: If you purchased ASP Isotopes securities during the Class Period, you may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the ASP Isotope Class Action Lawsuit, go to https://rosenlegal.com/submit-form/?case_id=32062 or call Phillip Kim, Esq. Toll-free at 866-767-3653 or email case@rosenlegal.com for information about the class action lawsuit. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must file with the Court no later than February 3, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSENADA LAW: We encourage investors to select qualified attorneys with a track record of success in leadership roles. Often, companies issuing notices do not have comparable experience, resources or any significant recognition from their peers. Many of these firms do not actually litigate securities class actions, but are simply intermediaries who refer clients or partner with law firms that actually litigate the cases. Be cautious when selecting an attorney. Rosen Law Firm represents investors throughout the world and concentrates its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest securities class action settlement against a Chinese company at that time. Rosen Law Firm Ranked No. 1 by ISS Securities Class Action (WA:) Services for several securities class action settlements in 2017. The company has ranked in the top four every year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone, the company earned more than $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of the Plaintiffs’ College. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

CASE DETAILS: According to the lawsuit, during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) ASP Isotopes exaggerated the potential effectiveness of its enrichment technology; (2) ASP Isotopes exaggerated the development potential of its high-assay low-enriched uranium facility; (3) ASP Isotopes overstated the results of ASP Isotopes’ nuclear fuels operating segment; and (4) as a result of the foregoing, defendants’ positive statements about ASP Isotopes’ business, operations and prospects were materially misleading and/or lacked a reasonable basis. When the true details hit the market, the lawsuit claims investors suffered damages.

To join the ASP Isotope Class Action Lawsuit, go to https://rosenlegal.com/submit-form/?case_id=32062 or call Phillip Kim, Esq. Toll-free at 866-767-3653 or email case@rosenlegal.com for information about the class action lawsuit.

No classes have been certified. Until a class is certified, you will not be represented by an attorney unless you hire one. You can select the lawyer of your choice. You can also remain an absent party member and do nothing at this time. An investor’s ability to participate in any potential future recovery is not dependent on serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook (NASDAQ:): https:/ /www.facebook.com/rosenlawfirm/.

Lawyer advertising. Previous results do not guarantee a similar result.

—————————-

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/235118

By Admin

Leave a Reply

Your email address will not be published. Required fields are marked *